Nektar Therapeutics (NKTR) is a publicly traded Healthcare sector company. As of November 11, 2026, NKTR trades at $38.40 with a market cap of $1.29B and a P/E ratio of -6.23. NKTR moved +1.51% today. Year to date, NKTR is -13.82%; over the trailing twelve months it is -35.33%. Its 52-week range spans $6.48 to $109.00. Analyst consensus is buy with an average price target of $132.46. Rallies surfaces NKTR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for NKTR, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $38.40 |
| Market Cap | $1.29B |
| P/E Ratio | -6.23 |
| EPS | $-6.51 |
| Dividend Yield | 0.00% |
| 52-Week High | $109.00 |
| 52-Week Low | $6.48 |
| Volume | 392.84K |
| Avg Volume | 0 |
| Revenue (TTM) | $54.59M |
| Net Income | $-157.13M |
| Gross Margin | 0.00% |
14 analysts cover NKTR: 0 strong buy, 10 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $132.46.